The AMN1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population designed for targeted disruption of the AMN1 gene in the HAP1 cell line. This polyclonal pool contains a heterogeneous collection of edited alleles, avoiding clonal selection biases and enabling robust functional studies. The population-level knockout model is particularly suited for applications requiring near-wild-type genetic complexity.
HAP1 is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia (CML) line, retaining the BCR-ABL1 fusion oncogene. Its haploid state simplifies genetic manipulation, enabling direct genotype-phenotype correlations and reducing off-target interference. The CML origin provides a disease-relevant context for studying oncogenic signaling and cancer-specific vulnerabilities.
AMN1 encodes a putative inhibitor of the mitotic exit network, governing the transition from mitosis to G1. It is thought to restrain the anaphase-promoting complex/cyclosome (APC/C), ensuring precise temporal control of mitotic exit. Mitotic kinases CDK1 and PLK1 likely phosphorylate AMN1, integrating checkpoint signals. Although direct binding partners remain uncharacterized in human cells, AMN1 is predicted to interact with additional mitotic exit network proteins, forming a regulatory hub that fine-tunes APC/C activity. Downstream, AMN1 influences activation of CDC14A phosphatase and degradation of Cyclin B, critical effectors of APC/C-mediated mitotic exit. The spindle assembly checkpoint, orchestrated by MAD2 and BUBR1, is intimately linked to this network, placing AMN1 at a key regulatory intersection.
In HAP1 cells, AMN1 disruption may perturb mitotic exit, leading to premature APC/C activation, chromosome missegregation, and genomic instability??hallmarks of leukemia progression. Combined with BCR-ABL1 signaling, AMN1 loss could reveal synthetic vulnerabilities or altered drug sensitivity. The near-haploid background affords clear genotype-phenotype dissection, enabling studies of mitotic catastrophe as a potential therapeutic strategy in CML.
These cells support diverse applications, including western blot analysis of mitotic markers, flow cytometric cell cycle profiling, immunofluorescence visualization of spindle defects, and viability or clonogenic assays for drug testing. The polyclonal format is ideal for pooled screens and population-level phenotypic analyses, capturing the variability of gene editing outcomes. For further information, please contact Ascent Research.
